Abatacept treatment for rheumatoid arthritis

Rheumatology

Volumn 50, Issue 3, 2011, Pages 437-449

  Schiff, Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Abatacept; Biological therapies; Clinical trials; Rheumatoid arthritis

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BLASTOMYCOSIS; BONE RADIOGRAPHY; BRONCHITIS; CANDIDIASIS; CELLULITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HERPES SIMPLEX ENCEPHALITIS; HOSPITAL INFECTION; HUMAN; INFECTION; INFESTATION; INFUSION SITE REACTION; LONG TERM CARE; LUNG CANCER; LYMPHOMA; NEOPLASM; NONMELANOMA SKIN CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PSORIASIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; TUBERCULOUS PERITONITIS; UNDIFFERENTIATED INFLAMMATORY ARTHRITIS; URINARY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952026221     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq287     Document Type: Review

References (75)

1. Landewe RB, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
2. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008;58:S126-35.
4. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
5. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
6. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
7. Aletaha D. ACR Concurrent Abstract Sessions: Rheumatoid Arthritis Therapy: Treatment Strategies. In: ACR/ARHP Annual Scientific Meeting. Philadelphia, PA, 2009.
8. Aletaha D, Neogi T, Silman AJ et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
9. Le Loet X, Berthelot JM, Cantagrel A et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006;65:45-50.
10. Kiely PD, Brown AK, Edwards CJ et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009;48:765-72.
11. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
12. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
13. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
14. Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68: 789-96.
15. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
16. Korhonen R, Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009;106:13-21.
17. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968-80.
18. Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-63.
19. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372: 375-82.
20. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009;68: 1153-8.
21. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009;36:1429-41.
22. Fleischmann RM, Emery P, Moreland LW et al. Golimumab, a new human anti-TNF-a monclonal antibody, administered subcutaneously every 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled, GO-BEFORE study. Abstract 983. Arthritis Rheum 2008; 58:S530.
23. Westhovens R, Robles M, Ximenes AC et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
24. Emery P, Durez P, Dougados M et al. The impact of T-cell co-stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept. Ann Rheum Dis 2010;69:510-6.
25. Westhovens R, Kremer JM, Moreland LW et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009;36:736-42.
26. Kremer JM, Russell A, Emery P et al. Abatacept demonstrates consistent safety and sustained improvements in efficacy through 5 years of treatment in biologic-nai{dotless}̈ve patients with RA. Abstract FRI0263. Ann Rheum Dis 2009;68:444.
27. Genovese MC, Schiff M, Luggen M et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54.
28. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13:559-75.
29. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-16.
30. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
31. Buch MH, Boyle DL, Rosengren S et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
32. Choy EH. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2009;27:510-8.
33. EMEA, London. Abatacept: summary of product characterisitics. 2010.
34. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90.
35. Yazici Y, Moniz Reed D, Covucci A, Becker JC, Westhovens R. Patients with early RA treated with abatacept plus MTX have a higher likelihood of increasing or maintaining initial improvements in signs and symptoms and physical function over time than those treated with MTX alone. Abstract 1688. Arthritis Rheum 2009;60: S631-2.
36. Westhovens R, Robles M, Nayiager S et al. Disease remission is achieved within two years in over half of methotrexate naive patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE trial. Abstract 638. Arthritis Rheum 2009;60: S239.
37. Bathon J, Genant H, Nayiager S et al. Reduced radiographic progression in patients with early rheumatoid arthritis (RA) treated with abatacept + methotrexate compared to methotrexate alone: 24 month outcomes. Abstract 639. Arthritis Rheum 2009;60:S239-40.
38. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
39. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
40. Westhovens R. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-nai{dotless}̈ve patients with RA. In: Proceedings of the EULAR, 2009 10-13th June, Copenhagen, Poster SAT0108.
41. Weisman MH, Durez P, Hallegua D et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33: 2162-6.
42. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
43. Dougados M, Kremer J, Le Bars M et al. Abatacept improves disease activity status over time in patients with rheumatoid arthritis and an inadequate response to methotrexate. Abstract SAT0099. Ann Rheum Dis 2009; 68:573-4.
44. Westhovens R, Dougados M, Hall S et al. Disease remission, radiographic non-progression and normalization of function achieved at Year 1 are sustained long-term in a majority of patients: 5-year outcomes with abatacept in biologic-naïve patients. Abstract 1657. Arthritis Rheum 2009;60:S618.
45. Genant H. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA. In: Proceedings of the EULAR, 2009 10-13th June, Copenhagen, Poster FRI0253.
46. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
47. Schiff M. Two-year efficacy and safety in abatacept-treated patients with RA who received continuous therapy or switched from infliximab to abatacept: the ATTEST trial. In: Proceedings of the EULAR, 2009 10-13th June, Copenhagen, Poster SAT0103.
48. Schiff M, Keiserman M, Moniz Reed D et al. An increasing proportion of patients achieve a low disease activity state or remission when switched from infliximab to abatacept regardless of initial infliximab treatment response: results from the ATTEST trial. In: ACR, 2009 10-16th October, Philadelphia, Poster 1659.
49. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
50. Genovese MC, Schiff M, Luggen M et al. Abatacept demonstrates consistent safety and sustained improvements in efficacy through 4 years of open-label treatment in patients with an inadequate response to anti-TNF therapy. Abstract 1689. Arthritis Rheum 2009;60:S632.
51. Schiff M, Pritchard C, Huffstutter JE et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-14.
52. Weinblatt M, Schiff M, Goldman A et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228-34.
53. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16.
54. Smitten AL, Covucci A, Simon TA. Descriptive analysis of serious infections, hospitalized infections and malignancies over time in the abatacept rheumatoid arthritis clinical development program: a safety update with >10,000 person-years of exposure. In: EULAR, 2008, Paris, Poster FRI0162.
55. Smitten AL, Simon TA, Qi K et al. Hospitalized infections in the abatacept RA clinical development program: an epidemiological assessment with >10,000 person-years of exposure. In: ACR Annual Scientific Meeting, 2008, San Francisco, CA, Poster 1674.
56. Smitten AL, Simon TA, Qi K et al. Malignancies in the abatacept RA clinical development program: an updated epidemiological assessment with >10,000 person-years of exposure. In: ACR Annual Scientific Meeting, 2008, San Francisco, CA, Poster 1675.
57. Smitten AL, Qi K, Simon TA, Becker JC. Autoimmune adverse events in the abatacept RA clinical development program: a safety analysis with >10,000 person-years of exposure. In: ACR Annual Scientific Meeting, 2008, San Francisco, CA, Poster 1673.
58. Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:S46-56.
59. Schiff M, Le Bars M, Gaillez C, Wu G, Poncet C, Genovese MC. Efficacy and safety of abatacept in patients with RA and an inadequate response to anti-TNF therapy by number of prior anti-TNF therapies used. Abstract SAT0102. Ann Rheum Dis 2009; 68:574-5.
60. Maxwell L, Singh A. Abatacept for rheumatoid arthritis. Cochrane Database of Syst Rev 2009;(4):CD007277.
61. Aletaha D, Landewe R, Karonitsch T et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
62. Kuriya B, Arkema V, Bykerk VP, Keystone E. Efficacy of initial methotrexate monotherapy versus combination therapy with a biologic agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Abstract 2010. Arthritis Rheum 2009;60: S751-2.
63. Singh A, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Syst Rev 2009;4:CD007848.
64. Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009;39: 18-29.
65. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
66. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003;42:617-21.
67. Salliot C, Gossec L, Ruyssen-Witrand A et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46:327-34.
68. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
69. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84.
70. Schiff MH, Burmester GR, Kent JD et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
71. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-44.
72. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.
73. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-77.
74. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:R45.
75. Kremer JM, Westhovens R, Leon M. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349: 1907-15.